anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a solid dispersion of swordlike atractylodes rhizome total terpene alcohols, a pharmaceutical composition and a preparation method thereof. The solid dispersion of swordlike atractylodes rhizome total terpene alcohols is to evenly disperse the swordlike atractylodes rhizome total terpene alcohols into a water soluble carrier to prepare the solid dispersion. The solid dispersion adopts the solvent evaporation-deposition and the spray drying method for preparation. The mass ratio of the swordlike atractylodes rhizome total terpene alcohols to the carrier material in the solid dispersion is 1:3-30. The prepared solid dispersion of the swordlike atractylodes rhizome total terpene alcohols can significantly improve the dissolution rate of the swordlike atractylodes rhizome total terpene alcohols in a dissolution medium, thereby improving the bioavailability. The solid dispersion can be further prepared into tablets, suspensions and a variety of solid and liquid pharmaceutical compositions according to the needs, thereby creating conditions for ensuring the physiological effects of the swordlike atractylodes rhizome total terpene alcohols and expanding the clinical and the application values of the swordlike atractylodes rhizome total terpene alcohols.
Approximately 70% to 80 % of stroke patients suffered from upper limb (UE) hemiparesis which limited their daily function and quality of life, as well as required considerable demands of long-term medical care. Robot-assisted training and mirror priming has been advocated as part of contemporary approaches. The robotic-assisted therapy mainly emphasized on the proximal part of UE, such as shoulder and elbow movement. While mirror priming strategy has been increasingly employed in the UE training, one question has been raised: the affected UE of stroke patients cannot complete the same movement as the sounded limb synchronously. This project will employ the robot-assisted system to assist patients to perform the grasping and releasing movement of both hands simultaneously while mirror priming strategy is applied, and, then, perform intensive and game-based finger movement training with the robotic assistance. This randomized controlled trial is the first study to explore the benefits of combined robotic-assisted therapy and mirror priming strategy in stroke patients. This proposed combined approach might be a novel combination of enhancing movement performance, daily function and quality of life for patients with stroke. This project will further explore the possible neuro-muscular mechanism underlying this combined mirror priming with robotic training. This project attempts to compare the cortical activation and neuromuscular control of patients with stroke and age-matched healthy adults in terms of electroencephalography (EEG) and muscle tone measurement. The findings of this study may lay an evidence-based foundation for bridging basic science and clinical application.
Administration of bevacizumab, carboplatin and paclitaxel once every 3 weeks, for at least 6 cycles, until disease progression (as assessed by the investigator), unacceptable toxicity, physician or participant decision or withdrawal of consent. If either chemotherapy or bevacizumab is discontinued, the participant may continue to receive the other ongoing therapy.
The intermittent theta-burst stimulation (iTBS) intensity for patients, applied under doctor supervision for a total of 5 days over one week (from Monday to Friday), will be set at 70% of the resting motor threshold. Stimulation will consist of bursts at a frequency of 50 Hz, with 3 bursts every 10 seconds, each burst lasting 2 seconds, totaling 600 bursts. Subsequently, the resting motor threshold will be adjusted to 80%, and a total of 2000 bursts will be delivered at a frequency of 10 Hz, repeated every 30 seconds, each lasting 10 seconds.
<P>PROBLEM TO BE SOLVED: To provide a prophylactic and/or ameliorative agent for arteriosclerosis in patients suffered from nephropathy, or to provide a functional food having prophylactic and/or ameliorative effects on arteriosclerosis in patients suffered from nephropathy.  <P>SOLUTION: The prophylactic and/or ameliorative agent for arteriosclerosis in patients suffered from nephropathy comprises coenzyme Q10 as active ingredient. Alternatively, the functional food having prophylactic and/or ameliorative effects on arteriosclerosis in patients suffered from nephropathy contains this agent as active ingredient. Use of coenzyme Q10 for preparing a prophylactic and/or ameliorative composition for arteriosclerosis in patients suffered from nephropathy is provided. A method for preventing and/or ameliorating arteriosclerosis in patients suffered from nephropathy involving intake of the composition containing the above agent as active ingredient is also provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
It is imperative to offer adequate community resources and psychosocial support, with a particular focus on enhancing resilience for children from low-income families. This study aims to determine the feasibility, acceptability, and preliminary efficacy of mountain craft training in enhancing resilience and self-esteem, reducing depressive symptoms, and improving the physical health of children from low-income families. This will be a pilot RCT using a two-group pre- and post-test within-subject design. The investigators plan to recruit 40 children in the Kwai Tsing District to participate in this study via the Asbury Methodist Social Service. Participants in the intervention group will be invited to join the mountain craft training programme. The research team will work with Mountain \& Stream (https://www.mtandstream.com/) to offer a tailor-made hiking training programme for Form 1 students. Participants will be invited to join a control intervention that mimics the time and attention received by participants in the intervention group but will be designed to have no specific effect on the outcome variables. The investigators hypothesise that participants who receive mountain craft training (six sessions) over 3 months will report significant improvements in: (i) resilience, (ii) self-esteem; (iii) depressive symptoms, and (iv) physical well-being compared with those in the placebo control group at the 6-month follow-up assessment.
All participants will receive the following: 1) a ClinCard and instructions for completing a weekly financial journal to record participants' spending patterns and social needs during the first 6 months of the study; 2) materials about financial literacy and community-based resources that provide support to low-income individuals; 3) description and instructions for follow-up assessments and check-ins; 4) a copy of signed medical release, consent, and HIPAA forms; 5) respondent-driven sampling referral cards; 6) 3 study referral cards, and 7) information about voter registration services provided through the Pulaski County Circuit and County Clerk's Office (https://www.pulaskiclerk.com/voter-registration/). Participants will be provided information about the importance of voting, restoration of voting rights, and the process of voting and sealing records.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Difference in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of infliximab-dyyb or of other infliximab products. 

In UC and CD clinical studies (UC Trial I and CD Trial I), approximately 64% subjects developed anti-drug antibodies to infliximab-dyyb following induction treatment with infliximab-dyyb intravenously and maintenance treatment with ZYMFENTRA by Week 54 [183/287 (64%) in subjects with UC, and 151/232 (65%) in subjects with CD] [see Clinical Studies (14)]. Among subjects with anti-drug antibodies, 92% had neutralizing antibodies [161/183 (88%) subjects with UC, and 147/151 (97%) subjects with CD]. Use of concomitant immunosuppressant agents (azathioprine, 6-mercaptopurine and methotrexate) appeared to reduce the frequency of ADA to infliximab-dyyb.

###  Anti-Drug Antibody Effects on Pharmacokinetics

Subjects who were positive for anti-drug antibodies showed lower infliximab-dyyb trough seum concentrations of infliximab-dyyb by approximately 30 to 40% compared to subjects who were negative for anti-drug antibodies. In some subjects with high titers of anti-drug antibodies and positive neutralizing antibodies, trough seum concentrations of infliximab-dyyb were below the lower limit of quantitation (<0.1 mcg/mL). There was no identified clinically significant effect of anti-drug antibodies on the safety and effectiveness of ZYMFENTRA in Study UC I and Study CD I.
Overweight and obese students were recruited from intervention schools. Students underwent MyBFF@school intervention programme that consisted of physical activity, nutrition and psychological modules for the duration of 6 months. MyBFF@school intervention programme were conducted by trained personnel that were stationed full-time at each intervention school.
The oil in water emulsion comprises a self tanning active substance, 0.1-10 wt.% of wax component with a fusion point by 30[deg] C, 1-30 wt.% of liquid oil component at 25[deg] C and 40-95 wt.% water. The oil component also contains polar oil component and non-polar oil component in the weight ratio of 7:1-8:1. ORGANIC CHEMISTRY - Preferred Compounds: The self tanning active substance is selected from mixture of dihydroxyacetone and erythrulose in 2:1-1:1. The wax component is selected from esters of saturated or unsaturated or branched or normal 14C-22C fatty acid of the pentaerythrits, dipentaerythrits or tripentaerythrits. The liquid oil component is selected from fatty acid esters, dialkyl carbonates, dialkylether, silicone oils, natural oils. The polar oils are selected from di-n-octylcarbonate, hexyl laurate, isostearylisononanoate, isostearyl palmitate, isostearyl stearate, isostearyl isostearate, isostearyl palmitate, capric triglyceride, thistle oil, benzoic acid, 12-15C alkylester, hexyldecanol, octyldodecanol and the non-polar oil component are selected from polydimethylsiloxane. POLYMER - Preferred Compounds: The polymer gelling agents is selected from homopolymer or copolymer of acrylic acid, acrylamide, acryloyldimethyltaurate or their salts.
FIELD: medicine, pharmacy. SUBSTANCE: composition has cyclosporin, at least one alcohol solvent having 2-3 carbon atoms, at least one nonionic polyhydroxyalkylene surface-active substance and at least one polyglycol. Surface-active substance is taken among the group including polyhydroxyethylene alcohols and monoesters of saturated acids and ethoxylated polyols with 4-6 carbon atoms. Polyglycol has molecular mass 800-1000 Da. Content of alcohol solvent is preferably 5-75 vol.% of composition and that of surface-active substance is 5-80%. Composition can be placed into solid capsule. Variant of composition involves additionally physiologically acceptable solvent being the composition is free of water practically. Method of attainment of immunosuppression in recipient body involves oral administration to recipient of the claimed composition. Invention ensures to administrate drug in patient by oral route that is more easily for patient. Invention can be used in transplantation of organs. EFFECT: improved properties of composition, absence of adverse effects. 16 cl, 6 dwg, 1 tbl, 42 ex
A prerequisite of proteomics is the ability to quantify many selected proteins simultaneously. Fluorescent sandwich immunoassays on microarrays hold appeal for such studies, since equipment and antibodies are readily available, and assays are simple, scalable and reproducible. To attain adequate sensitivity and specificity, however, a general method of immunoassay amplification is required. Coupling of isothermal rolling circle amplification (RCA) to universal antibodies can be used for this purpose: RCA on a synthetic DNA circle is initiated by a complementary oligonucleotide attached to an anti- biotin antibody; single-stranded RCA product remains -attached to the antibody, and is detected by hybridization of complementary, fluorescent oligonucleotides. 51 cytokines were measured simultaneously on microarrays with signal amplification by RCA with high specificity, femtomolar sensitivity and 4 log quantitative range. This cytokine microarray was used to measure secretion from human Dendritic cells (DCs) induced by lipopolysaccharide (LPS) or tumor necrosis factor-alpha (TNF-.alpha.). Rapid secretion of inflammatory cytokines such as MIP-1.beta., IL-8, and IP-10 was induced by LPS. Eotaxin-2 and I-309 were found to be induced by LPS, and MDC, TARC, sIL-6R, and sTNF-RI were found to be induced by TNF-.alpha.. Since microarrays can accommodate.sim.1000 sandwich immunoassays of this type, a relatively small number of RCA microarrays appears to offer a tractable approach for proteomic surveys.
This is a randomized controlled pilot study of a post discharge community based patient engagement program for stroke patients discharged with a new carer after a period of in-hospital rehabilitation. Potential cases are identified within 2 weeks after admission into rehabilitation wards and randomized into either intervention group or usual care (control) group. Patients undergo the usual pre-discharge planning while in ward with predischarge assessment carried out by an independent (blinded) assessor. The control group are referred to receive the usual post-discharge community and rehabilitation backup. The intervention group has access to a special telephone hotline, home visits by team member within 1 week after discharge, patient diary to record home monitoring and back up of a specialist lead patient engagement clinic located in Kowloon Hospital. After 12 weeks, another home visit will be arranged for a repeat assessment by an independent (blinded) assessor. The outcomes to be measured include service parameters such as unplanned medical readmissions, AED attendances, length of stay at acute and rehabilitation units. Patient related parameters such as mortality, institutionalization, functional outcomes, mood, quality of life and complications will be measured as well as a carer strain and satisfaction survey.
The population pharmacokinetics of clofarabine were studied in 40 pediatric patients aged 2 to 19 years (21 males/19 females) with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). At the given 52 mg/m2 dose, similar concentrations were obtained over a wide range of body surface areas (BSAs). Clofarabine was 47% bound to plasma proteins, predominantly to albumin. Based on non-compartmental analysis, systemic clearance and volume of distribution at steady­state were 28.8 L/h/m2 and 172 L/m2, respectively. The terminal half-life was 5.2 hours. No apparent difference in pharmacokinetics was observed between patients with ALL and AML or between males and females. 

No relationship between clofarabine or clofarabine triphosphate exposure and toxicity or response was found in this population. 

Based on 24-hour urine collections in the pediatric studies, 49% to 60% of the dose is excreted in the urine unchanged. In vitro studies using isolated human hepatocytes indicate very limited metabolism (0.2%). The pathways of non-hepatic elimination remain unknown.

Clofarabine has not been studied in patients with hepatic impairment

Drug-Drug Interactions

In vitro studies suggested that clofarabine undergoes limited metabolism and does not inhibit or induce major CYP enzymes. CYP inhibitors and inducers are unlikely to affect the metabolism of clofarabine. Clofarabine is unlikely to affect the metabolism of CYP substrates. However, no in vivo drug interaction studies have been conducted. 

An in vitro transporter study suggested that clofarabine is a substrate of human transporters OAT1, OAT3, and OCT1. A preclinical study using perfused rat kidney demonstrated that the renal excretion of clofarabine was decreased by cimetidine, an inhibitor of the hOCT2. Although the clinical implications of this finding have not been determined, signs of clofarabine injection toxicity should be monitored when administered with other hOAT1, hOAT3, hOCT1 and hOCT2 substrates or inhibitors.
Participants will sit fully clothed on the magnetic stimulator chair, with knees apart at about the width of their shoulders, feet flat on the floor. The stimulator will be activated and the intensity gradually increased as tolerated by the participant up to an intensity of 100%. There are a total of 6 treatment sessions (twice per week) over 3 weeks.
Chidamide 30mg/d per os (p.o.), twice per week, begins at day 1; Cladribine 5mg/m2/d, intravenous injection (i.v.), days 1-5, once per day; A cycle is during 28 days.
Mutation profiling by next-generation sequencing (NGS) has facilitated understanding of the molecular pathogenesis of acute myeloid leukemia (AML), and has been incorporated into the new disease classification (International Consensus Classification; ICC) and risk classification (European LeukemiaNet [ELN] 2022; ELN2022). We compared disease subtypes between the previous disease classification (4th edition of the WHO classification; WHO-4) and the ICC in 91 patients with AML diagnosed at our institution. We also compared disease risk classifications using the previous risk classification (ELN2017) and the ELN2022. Targeted sequencing of bone marrow samples was conducted at Kyoto University. We found that entities under AML with recurrent genetic abnormalities were well-established, with almost no change from the WHO-4 to the ICC. In contrast, 16.7% of cases of AML, not otherwise specified in the WHO-4 were reclassified into AML with mutated TP53, and 36.7% were reclassified into AML with myelodysplasia-related gene mutations or cytogenetic abnormalities per the ICC. Meanwhile, the ELN2017 and ELN2022 showed no difference in concordance indexes in multivariate Cox regression analysis for progression-free and overall survival. The superiority of the ELN2022 over the ELN2017 could not be confirmed in our single-center retrospective study, and further investigation including multicenter prospective studies is needed.
PURPOSE:To industrially obtain the subject compound of high quality useful in the medical field without any loss in raw materials by feeding a solution of a lipid having the ability to form liposome films in an organic solvent into a tubular heater at a prescribed rate, heating and evaporating the solvent, etc. CONSTITUTION:A solution of a lipid having the ability to form liposome films in an organic solvent (e.g. pentane or hexane) in a raw material tank 1 is fed into a tubular heater 2 normally at a prescribed rate of about 1-100l/hr and heated therein to evaporate the organic solvent and provide a mixture of substantially a solid substance with vapor of the solvent. The resultant mixture is then introduced into a vacuum changer 3 under <=300mmHg at a high speed to instantaneously volatilize the organic solvent and dry the solid substance, which is then recovered in a powder recovery device 6. Thereby, the objective powder for preparing the liposome is obtained. The lipid powder excellent in hydrating power is obtained by the afore-mentioned method.
To identify different patterns of neurogenic lower urinary tract dysfunction management among Chinese community-dwelling individuals with spinal cord injury and explore the factors associated with latent classes. This was a cross-sectional study conducted in communities throughout China Mainland. Participants were recruited through the China Association of Persons with Physical Disability and a total of 2582 participants was included in the analysis. The data were collected by a questionnaire consisting of socio-demographic factors, disease-related factors, and a list of 8 bladder management methods. Latent class analysis was used to identify different latent classes of neurogenic lower urinary tract dysfunction management. Then the multinomial logistic regression was applied to analyze the relationship between neurogenic lower urinary tract dysfunction management patterns and socio-demographic and disease-related factors. Neurogenic lower urinary tract dysfunction management pattern among community-dwelling individuals with spinal cord injury was divided into four latent classes: "urinal collecting apparatus dominated pattern" (40.3%), "bladder compression dominated pattern" (30.7%), "intermittent catheterization dominated pattern" (19.3%) and "urethral indwelling catheterization dominated pattern" (9.6%). Multinomial logistic regression analysis found that the employment status, residential region, nursing need, payment method for catheterization products, hand function, time since spinal cord injury, urinary incontinence and concerns about social interaction affected by urination problems were significantly associated with latent classes. Only 19.3% of people used the intermittent catheterization as their main neurogenic lower urinary tract dysfunction management method. More attention needs to be paid to the promotion of the standardization process of intermittent catheterization in community-dwelling individuals with spinal cord injury. The associated factors of the four classes can be used for tailored and targeted interventions to increase the use of intermittent catheterization.
TNF acts as one pathogenic driver for inducing intestinal epithelial cell (IEC) death and substantial intestinal inflammation. How the IEC death is regulated to physiologically prevent intestinal inflammation needs further investigation. Here, we report that EF-hand domain-containing protein D2 (EFHD2), highly expressed in normal intestine tissues but decreased in intestinal biopsy samples of ulcerative colitis patients, protects intestinal epithelium from TNF-induced IEC apoptosis. EFHD2 inhibits TNF-induced apoptosis in primary IECs and intestinal organoids (enteroids). Mice deficient of Efhd2 in IECs exhibit excessive IEC death and exacerbated experimental colitis. Mechanistically, EFHD2 interacts with Cofilin and suppresses Cofilin phosphorylation, thus blocking TNF receptor I (TNFR1) internalization to inhibit IEC apoptosis and consequently protecting intestine from inflammation. Our findings deepen the understanding of EFHD2 as the key regulator of membrane receptor trafficking, providing insight into death receptor signals and autoinflammatory diseases.
A computer implemented method, apparatus, and computer program product for modifying neuropsychiatric treatment plans based on efficacy of treatment. A current treatment plan comprising a first set of therapies to treat a set of neuropsychiatric conditions and portions of the medical literature associated with the set of neuropsychiatric conditions is retrieved. A set of brain scans of the patient is analyzed to determine a set of changes over time associated with the set of neuropsychiatric conditions. The portions of the medical literature and the set of changes are analyzed to determine a patient rate of response to the treatment plan. If the patient rate of response falls below a threshold expected rate, a set of alternative treatments for the patient is identified. A modified treatment plan is generated using the set of alternative treatments.
After induction of general anaesthesia, an ESP catheter will be inserted at the level of T5. A bolus dose of 20 ml 0.25% Levobupicaine will be administered into the ESP space. Two hours post bolus administration, patients will receive programmed intermittent bolus of local anaesthetic: 20mls 0.125% levobupivacaine every two hours.
Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on day 1. Treatment repeats every 14 days for cycles 1-6 and then every 21 days for subsequent cycles. Patients may continue to receive sEphB4-HSA treatment until no longer clinically benefiting (PCWG3), unacceptable toxicity, treatment delay \>= 4 weeks, or prohibitive illness/change in patient?s condition, or patient decides to withdraw from study.